Contents
There are two FDA-approved drugs for male-pattern hair loss and one for women, despite the fact that up to 80% of men and almost 50% of women experience significant hair loss throughout their lives.
But one chemical has stepped up to the task as millions of people across the world look for a means to slow down or stop baldness.
As stated in recent hair loss research from the University of California, Riverside, understanding transforming growth factor beta (TGF-) may be the key to curing baldness.
The study, which was published in the Biophysical Journal, identified TGF- as the moderator of the hair follicle growth cycle, dictating when hair follicle cells grow and when they die. TGF is one of many tiny proteins known as cytokines that help control other immune system cells and blood cells.
The research also explores regenerative medicine by looking at hair follicles, a source of stem cells. It offers a model to hasten wound healing. But this isn’t the only research out there.
Below, we invite you to check out the latest in peer-reviewed science on hair loss.
No abstract
BK channels are expressed in mouse cochlear inner hair cells (IHCs) and exhibit Ca^(2+)-independent activation at negative potentials. However, the […]
Heterozygous R391 TUBB4B pathogenic variations are responsible for an association of hearing loss and retinal dystrophy in human. With the goal of […]
[This corrects the article DOI: 10.3389/fphar.2024.1370833.].
Androgenetic alopecia is a chronic dermatological condition in which genetically predisposed individuals undergo progressive hair loss secondary to […]
KeraMedix, a brand-new intriguing firm focused on hair development, has once more arisen from Korea.
Researchers from Kyung Hee and Konkuk Universities in South Korea published their paper, “Keratin-mediated hair development and its underlying biological mechanism,” on November 19, 2022 in the Communications Biology magazine of Nature Portfolio.
According to this peer-reviewed study, an exclusive type of injectable keratin can promote hair development in an animal model. The study is highly detailed and has a ton of information for anyone who want to look over its supporting documentation. However, we’re quite aware that the majority of this readership is only concerned with the financial benefits of such an injectable technology.
According to its website, KeraMedix is a bio-venture firm with headquarters in Seoul, South Korea, and was established in 2017.
The company’s CEO is Dr. Song-wook Han.
Four prospective medicines are now visible in KeraMedix’s pipeline (shown below): first- and second-generation injectables for hair growth, an injectable for diabetic ulcers, and an injectable for skin rejuvenation.
It’s fascinating to note that a sophisticated technique actually uses human hair to create the keratin protein that is employed in these injectable medicines.